Browse by Audience
Skip to content
Papers of the Week
Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
Authors
Daveson AJM, Stubbs R, Polasek TM, Isola J, Anderson R, Tye-Din JA, Schoeman M, Lionnet C, Mei SLCY, Mihajlović J, Wirth M, Peelen E, Schreieck A, Kohlhof H, Vitt D, Muehler A, Buriánek FAbstract
IMU-856 is an orally available and systemically acting small molecule modulator of sirtuin 6 (SIRT6), a protein that serves as a transcriptional regulator of bowel epithelium regeneration. We aimed to evaluate the safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856 in healthy participants and in patients with coeliac disease.